Detalhe da pesquisa
1.
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Blood
; 126(6): 779-89, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26002965
2.
Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
Bioorg Med Chem Lett
; 23(6): 1588-91, 2013 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23414803
3.
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation.
J Med Chem
; 66(23): 16388-16409, 2023 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37991844
4.
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2).
J Med Chem
; 66(23): 15750-15760, 2023 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38009718
5.
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.
Blood
; 114(2): 338-45, 2009 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-19417207
6.
Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Bioorg Med Chem Lett
; 21(22): 6793-9, 2011 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21978683
7.
Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates.
Methods Mol Biol
; 2365: 283-300, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34432250
8.
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
J Med Chem
; 63(13): 6648-6676, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130004
9.
Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by beta-lactamases.
Antimicrob Agents Chemother
; 48(2): 477-83, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14742198